We believe that more in vitro studies involving other phage types and bacterial genera, followed by in vivo studies, i.e., on Galleria mellonella or Caenorhabditis elegans models, could deliver more detailed data on phage–lactoferrin synergy and effectivity, helping to answer the question if phage–AMPs mixtures can be used as one of the treatment methods of multi-drug-resistant infections. The gene discussed is ADSL; the disease is infection.